NASDAQ:TRHC - Tabula Rasa HealthCare Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $48.03
  • Forecasted Upside: 56.20 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.92 (6.66%)

This chart shows the closing price for TRHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tabula Rasa HealthCare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRHC

Analyst Price Target is $48.03
▲ +56.20% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Tabula Rasa HealthCare in the last 3 months. The average price target is $48.03, with a high forecast of $55.00 and a low forecast of $40.00. The average price target represents a 56.20% upside from the last price of $30.75.

This chart shows the closing price for TRHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 contributing investment analysts is to hold stock in Tabula Rasa HealthCare. This rating has held steady since December 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/12/2021Royal Bank of CanadaSet Price Target$48.26Low
7/11/2021Royal Bank of CanadaReiterated RatingBuyLow
5/27/2021Robert W. BairdInitiated CoverageOutperform$53.00High
5/10/2021SVB LeerinkBoost Price TargetMarket Perform$43.00 ➝ $49.00High
5/7/2021Piper SandlerBoost Price TargetNeutral$41.00 ➝ $45.00Low
3/2/2021Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral$40.00Medium
3/2/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$40.00 ➝ $41.00Medium
3/1/2021TruistDowngradeBuy ➝ Hold$41.00 ➝ $42.00Low
2/25/2021SVB LeerinkLower Price TargetMarket Perform$47.00 ➝ $43.00High
2/24/2021Piper SandlerDowngradeOverweight ➝ Neutral$40.00 ➝ $41.00High
2/24/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$40.00Low
2/2/2021Royal Bank of CanadaBoost Price TargetOutperform$54.00 ➝ $70.00Low
1/15/2021Stifel NicolausDowngradeBuy ➝ Hold$52.00High
11/5/2020TruistLower Price Target$61.00 ➝ $41.00Medium
11/4/2020Piper SandlerLower Price TargetOverweight$59.00 ➝ $40.00High
11/4/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$56.00 ➝ $38.00High
11/4/2020BenchmarkLower Price TargetBuy$65.00 ➝ $55.00High
9/23/2020Royal Bank of CanadaReiterated RatingBuy$57.00Low
8/12/2020Truist FinancialLower Price Target$72.00 ➝ $61.00Low
8/6/2020Wells Fargo & CompanyLower Price TargetEqual Weight$53.00 ➝ $46.00Medium
8/6/2020Piper SandlerLower Price TargetOverweight$68.00 ➝ $59.00Medium
8/6/2020SVB LeerinkLower Price TargetOutperform$65.00 ➝ $56.00Medium
8/5/2020BenchmarkLower Price TargetBuy$84.00 ➝ $75.00High
7/2/2020SunTrust BanksInitiated CoverageBuy$72.00High
6/25/2020Cantor FitzgeraldLower Price TargetPositive ➝ Overweight$85.00 ➝ $83.00Low
5/11/2020BenchmarkLower Price TargetBuy$90.00 ➝ $84.00Low
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$70.00Medium
4/13/2020SVB LeerinkInitiated CoverageOutperform$65.00High
2/28/2020Wells Fargo & CompanyReiterated RatingHoldHigh
2/28/2020Piper SandlerBoost Price Target$66.00 ➝ $72.00Low
2/14/2020OppenheimerInitiated CoverageBuy$78.00Low
1/17/2020William BlairReiterated RatingOutperformLow
1/8/2020Wells Fargo & CompanyLower Price TargetEqual Weight$55.00 ➝ $50.00Low
11/8/2019Cantor FitzgeraldLower Price TargetOverweight$99.00 ➝ $85.00High
11/8/2019Piper Jaffray CompaniesLower Price TargetOverweight$78.00 ➝ $66.00High
10/18/2019Piper Jaffray CompaniesSet Price TargetBuy$78.00N/A
8/30/2019Stifel NicolausUpgradeHold ➝ Buy$50.00 ➝ $75.00High
5/13/2019Cantor FitzgeraldReiterated RatingBuy$99.00High
5/9/2019Piper Jaffray CompaniesBoost Price TargetOverweight$73.00 ➝ $78.00High
4/17/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$58.00Medium
3/11/2019First AnalysisUpgradeOutperform ➝ Strong-Buy$58.33High
3/6/2019OppenheimerLower Price TargetOutperform$97.00 ➝ $88.00High
2/28/2019Cantor FitzgeraldReiterated RatingBuy$99.00High
1/8/2019BenchmarkInitiated CoverageBuy$85.00Medium
12/6/2018Piper Jaffray CompaniesReiterated RatingOverweight$80.00Medium
11/7/2018Chardan CapitalBoost Price TargetBuy$77.00 ➝ $91.00High
11/6/2018Cantor FitzgeraldReiterated RatingBuy$99.00High
10/11/2018CitigroupBoost Price TargetBuy$100.00Medium
9/19/2018Robert W. BairdBoost Price TargetOutperform$70.00 ➝ $90.00Low
9/11/2018Stifel NicolausInitiated CoverageHold$95.00Low
9/6/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$99.00Low
8/23/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $86.00High
8/9/2018CitigroupBoost Price TargetBuy ➝ Buy$57.00 ➝ $76.00High
8/8/2018Piper Jaffray CompaniesBoost Price TargetOverweight$71.00Medium
8/8/2018Robert W. BairdReiterated RatingBuy$70.00High
6/18/2018Robert W. BairdBoost Price TargetOutperform$50.00 ➝ $65.00Low
5/18/2018Chardan CapitalBoost Price TargetBuy$50.00 ➝ $68.00Low
5/9/2018CitigroupReiterated RatingBuy$57.00High
5/9/2018Piper Jaffray CompaniesReiterated RatingOverweight$46.00High
3/16/2018Chardan CapitalReiterated RatingBuy ➝ Buy$46.00 ➝ $50.00High
3/13/2018CIBCReiterated RatingOutperform ➝ Outperform$35.00 ➝ $47.00Medium
3/13/2018OppenheimerBoost Price TargetOutperform$35.00 ➝ $47.00High
3/13/2018William BlairReiterated RatingOutperformHigh
3/13/2018Piper Jaffray CompaniesBoost Price TargetOverweight$43.00High
1/4/2018CitigroupInitiated CoverageBuyHigh
12/18/2017OppenheimerInitiated CoverageOutperform$35.00Low
12/11/2017William BlairInitiated CoverageOutperform ➝ OutperformLow
11/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$35.00N/A
11/1/2017First AnalysisInitiated CoverageOverweight$41.00N/A
10/24/2017Piper Jaffray CompaniesReiterated RatingBuy$29.00N/A
10/19/2017Wells Fargo & CompanyBoost Price TargetMarket Perform$21.00 ➝ $27.00N/A
10/17/2017Robert W. BairdReiterated RatingOutperform$22.00 ➝ $30.00N/A
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$20.00 ➝ $29.00Low
9/7/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$17.00 ➝ $21.00High
8/30/2017UBS GroupBoost Price TargetBuy ➝ Buy$18.00 ➝ $25.00Medium
8/9/2017Piper Jaffray CompaniesReiterated RatingOverweight$19.00 ➝ $20.00Low
8/8/2017Robert W. BairdBoost Price TargetOutperform$17.00 ➝ $18.00High
8/8/2017Chardan CapitalBoost Price TargetBuy ➝ Buy$19.50 ➝ $21.00High
7/14/2017Stifel NicolausReiterated RatingBuy$16.00Low
7/10/2017Chardan CapitalInitiated CoverageBuy ➝ Buy$19.50Low
5/25/2017UBS GroupReiterated RatingBuy$18.00 ➝ $17.00N/A
5/2/2017Stifel NicolausLower Price TargetBuy ➝ Buy$19.00 ➝ $16.00Medium
3/14/2017Piper Jaffray CompaniesBoost Price TargetOverweight$18.00 ➝ $19.00High
3/14/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$17.00 ➝ $19.00High
1/19/2017Robert W. BairdSet Price TargetBuy$17.00N/A
10/24/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
10/24/2016UBS GroupInitiated CoverageBuy$18.00N/A
10/24/2016Robert W. BairdInitiated CoverageOutperform$17.00N/A
10/24/2016Stifel NicolausInitiated CoverageBuy$17.00N/A
10/24/2016Piper Jaffray CompaniesInitiated CoverageOverweight$18.00N/A
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Tabula Rasa HealthCare logo
Tabula Rasa Healthcare, Inc. is a healthcare technology company, which engages in the development of solutions designed for pharmacists, providers, and patients to optimize medication regimens. It operates through the following segments: CareVention HealthCare and MedWise HealthCare. The CareVention HealthCare segment provides services, PACE, which is a center for Medicare & Medicaid services, or CMS, sponsored program providing medical and social services. Its brands include CareKinesis, Capstone Risk Adjustment Services, PACElogic, TruChart, PeakTPA, PersonifilRx, and Pharmastar. The MedWise HealthCare segment provides Medication Therapy Management, or MTM, software and services for Medicare, Medicaid, and commercial health plans, and also provides a cloud-based patient engagement software and services. It offers cloud-based software and clinical pharmacist services through its brands, including MedWise, SinfoníaRx, RxCompanion, PrescribeWellness, and DoseMeRx. The company was founded by Calvin H. Knowlton, Orsula V. Knowlton, and Michael Greenhalgh in April 2009 and is headquartered in Moorestown, NJ.
Read More

Today's Range

Now: $30.75
Low: $28.86
High: $31.45

50 Day Range

MA: $36.70
Low: $28.79
High: $48.74

52 Week Range

Now: $30.75
Low: $27.01
High: $69.31


1,135,700 shs

Average Volume

315,365 shs

Market Capitalization

$763.92 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Tabula Rasa HealthCare?

The following Wall Street research analysts have issued stock ratings on Tabula Rasa HealthCare in the last twelve months: Benchmark Co., Cantor Fitzgerald, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Truist, and Zacks Investment Research.
View the latest analyst ratings for TRHC.

What is the current price target for Tabula Rasa HealthCare?

8 Wall Street analysts have set twelve-month price targets for Tabula Rasa HealthCare in the last year. Their average twelve-month price target is $48.03, suggesting a possible upside of 56.2%. Benchmark Co. has the highest price target set, predicting TRHC will reach $55.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $40.00 for Tabula Rasa HealthCare in the next year.
View the latest price targets for TRHC.

What is the current consensus analyst rating for Tabula Rasa HealthCare?

Tabula Rasa HealthCare currently has 5 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TRHC, but not buy more shares or sell existing shares.
View the latest ratings for TRHC.

What other companies compete with Tabula Rasa HealthCare?

Other companies that are similar to Tabula Rasa HealthCare include American Well, Xometry, TechTarget, GreenSky, EVO Payments, Repay, CBIZ, Radware, B. Riley Financial, Alight, Paysafe, Conduent, Cielo, OptimizeRx and Uxin.

How do I contact Tabula Rasa HealthCare's investor relations team?

Tabula Rasa HealthCare's physical mailing address is 228 STRAWBRIDGE DRIVE SUITE 100, MOORESTOWN NJ, 08057. The company's listed phone number is (866) 648-2767 and its investor relations email address is [email protected] The official website for Tabula Rasa HealthCare is